113 related articles for article (PubMed ID: 15787207)
1. [Effect of atypical antipsychotics on metabolism].
Bakos CD; Berecz R; Degrell I
Neuropsychopharmacol Hung; 2004 Jun; 6(2):86-9. PubMed ID: 15787207
[TBL] [Abstract][Full Text] [Related]
2. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
[TBL] [Abstract][Full Text] [Related]
3. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
[TBL] [Abstract][Full Text] [Related]
4. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Liu ZN; Zhai JG; Guo XF; Guo WB; Tang JS
Psychopharmacology (Berl); 2006 Jul; 186(4):572-8. PubMed ID: 16601995
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.
Kaushal J; Bhutani G; Gupta R
Singapore Med J; 2012 Jul; 53(7):488-92. PubMed ID: 22815019
[TBL] [Abstract][Full Text] [Related]
6. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels.
Roerig JL; Steffen KJ; Mitchell JE; Crosby RD; Gosnell BA
J Clin Psychopharmacol; 2008 Feb; 28(1):21-6. PubMed ID: 18204336
[TBL] [Abstract][Full Text] [Related]
8. Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study.
Vidarsdottir S; Vlug P; Roelfsema F; Frölich M; Pijl H
J Clin Psychiatry; 2010 Sep; 71(9):1205-11. PubMed ID: 20441717
[TBL] [Abstract][Full Text] [Related]
9. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.
Guina J; Roy S; Gupta A; Langleben DD; Elman I
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28573760
[TBL] [Abstract][Full Text] [Related]
10. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Alméras N; Després JP; Villeneuve J; Demers MF; Roy MA; Cadrin C; Mottard JP; Bouchard RH
J Clin Psychiatry; 2004 Apr; 65(4):557-64. PubMed ID: 15119921
[TBL] [Abstract][Full Text] [Related]
11. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB
J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222
[TBL] [Abstract][Full Text] [Related]
12. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model.
Boyda HN; Tse L; Procyshyn RM; Wong D; Wu TK; Pang CC; Barr AM
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):945-54. PubMed ID: 20452386
[TBL] [Abstract][Full Text] [Related]
13. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.
Albaugh VL; Singareddy R; Mauger D; Lynch CJ
PLoS One; 2011; 6(8):e22662. PubMed ID: 21857944
[TBL] [Abstract][Full Text] [Related]
14. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.
Fell MJ; Anjum N; Dickinson K; Marshall KM; Peltola LM; Vickers S; Cheetham S; Neill JC
Psychopharmacology (Berl); 2007 Oct; 194(2):221-31. PubMed ID: 17581744
[TBL] [Abstract][Full Text] [Related]
15. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients.
Chiu CC; Chen KP; Liu HC; Lu ML
J Clin Psychopharmacol; 2006 Oct; 26(5):504-7. PubMed ID: 16974193
[TBL] [Abstract][Full Text] [Related]
16. Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study.
Rittmannsberger H; Fellinger J; Foff C; Walli G; Zaunmüller T
Int J Psychiatry Clin Pract; 2012 Mar; 16(1):8-17. PubMed ID: 22122649
[TBL] [Abstract][Full Text] [Related]
17. Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.
Lasser RA; Mao L; Gharabawi G
Schizophr Res; 2004 Feb; 66(2-3):163-7. PubMed ID: 15061249
[TBL] [Abstract][Full Text] [Related]
18. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
19. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.
Graham KA; Perkins DO; Edwards LJ; Barrier RC; Lieberman JA; Harp JB
Am J Psychiatry; 2005 Jan; 162(1):118-23. PubMed ID: 15625209
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.
Park S; Sang Mee Hong ; Il Sung Ahn ; Sung Hoon Kim
J Psychopharmacol; 2010 Jul; 24(7):1105-14. PubMed ID: 19965940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
